Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Regulatory and Compliance Updates news
(page 10)
27 March 2026
RWE approved for Nordseecluster B offshore wind farm
Planning approval granted for Nordseecluster B, adding 900 MW to reach 1.6 GW (660 MW A under construction). Full output ~6.5 TWh/yr; B due early 2029; 110 MW PPA with Amazon.
27 March 2026
GSK bepirovirsen accepted for EMA review for chronic hepatitis B
EMA accepted bepirovirsen MAA for chronic hepatitis B after Phase III B‑Well 1/2 showed higher functional cure rates vs standard of care; safety profile acceptable.
26 March 2026
FDA approves Novo Nordisk Awiqli, first once-weekly basal insulin for adults with type 2 diabetes
ONWARDS trials (~2,680 pts) showed A1C reductions vs daily basal; safety aligned with class. Key risks: hypoglycemia, injection-site reactions, weight gain. US launch pending
26 March 2026
Equinor completes investigation into Mongstad benzene exposure
Probe: prolonged benzene exposure during filling—task overran; no re-assessment; respirators insufficient. Naphtha→glycol; more PPE, detector training and a safety engineer; authorities notified.
26 March 2026
Novo Nordisk gains US approval for Awiqli, first once‑weekly basal insulin for adults with type 2 diabetes
ONWARDS phase‑3 (~2,680 adults) showed HbA1c reductions vs daily basal insulin with similar safety. US launch planned H2 2026; also approved in EU and 13 other countries.
26 March 2026
BASF pressure-sensitive adhesive for PET labels compatible with recycling
RecyClass-approved acResin UV 3532 PSA enables filmic labels to wash off in standard PET recycling, supporting high-clarity, design-friendly recyclable bottles.
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
25 March 2026
EU dialogue on cement industry's low‑carbon transition
Stakeholders urged lead markets, funding (Industrial Decarbonisation Bank), standards, CCS, CO2 transport & storage, skills, stable ETS to speed decarbonisation and competitiveness
25 March 2026
Nouryon secures halal certification in China for personal care and cleaning ingredients
Chinese Boxing and Ningbo plants gained halal certification for fatty amines, quats and chelating agents, enabling wider access to halal personal-care and cleaning markets worldwide.
25 March 2026
Merck to acquire Terns Pharmaceuticals, adding TERN‑701 for CML
Acquirer to buy target biotech at $53/share (~$6.7B equity, ~$5.7B net). Lead oral allosteric BCR::ABL1 TKI showed week‑24 molecular responses in Phase1/2; expected Q2 2026.
25 March 2026
Boehringer Ingelheim launches two late-stage medicines, 2025 sales up 7.3%
R&D spend rose to €6.4bn (22.9% of sales); reached 70M patients; Human Pharma and Animal Health grew—JARDIANCE and OFEV expanded; Animal Health up 6.5% with NEXGARD leading; pipeline >80 projects.
25 March 2026
Mitsui Chemicals Obtains ISCC PLUS Certification for ACTCOL
Nagoya Works gained ISCC PLUS for ACTCOL (Jan 2026). Certification covers ACTCOL PPG and polymer polyol resin premix; group to expand mass‑balance biomass and chemically recycled products (~50 total).
24 March 2026
Brenntag opens Asia Pacific’s first VDA-certified AdBlue site
VDA-certified AdBlue plant in Samut Prakan, Thailand delivers ISO 22241-compliant production with closed handling and controlled filling, ensuring pure, traceable diesel exhaust fluid supply.
24 March 2026
MOL cleared by US to proceed with NIS majority‑stake acquisition talks
U.S. OFAC extended the negotiation license to 22 May 2026, allowing finalization of sale documents and U.S. banks' participation; deal would transfer 56.15% stake, pending approvals.
24 March 2026
WuXi Biologics posts record 2025 results
2025 revenue +16.7% to RMB21.8bn; gross margin +500bps to 46%; EBITDA +38%; net profit +45%; 209 new integrated projects; backlog US$23.7bn; bi-/multi-specifics >120% growth
24 March 2026
UPM and Paramelt launch bio-based paper food packaging
Bio-based paper food-packaging with strong grease barrier at low coat weights. Recyclable and home-compostable. Runs on existing packaging lines; suited to bakery/fast-food
23 March 2026
WACKER expands silicone emulsion production in India
New Panagarh GMP-certified silicone emulsion plant boosts local capacity, adds 60 jobs, serves cosmetics/personal-care customers, lets Amtala shift toward R&D and innovation.
23 March 2026
TotalEnergies ends U.S. offshore wind projects, returns leases to DOI
Signed settlements to relinquish Carolina Long Bay and New York Bight offshore wind leases, recover fees and reinvest equal funds into U.S. gas/LNG and power, citing cost and affordability concerns.
23 March 2026
Ercros: EcoVadis Gold, 85/100
Ranks in the 98th percentile; environment & ethics 91, labour & human rights 90. Advanced management, many KPIs provided; 100/100 for endorsements, measures and certifications
23 March 2026
BASF converts Ludwigshafen acid chlorides and chloroformates to 100% renewable electricity credits
Average product carbon footprint cut ~19% in 2025; plant modernization raised capacity ~30%; customers get lower‑PCF supplies without recertification, aiding Scope 3 reductions.
23 March 2026
Chugai obtains MHLW approval for Lunsumio–Polivy combo in relapsed/refractory large B‑cell lymphoma
Japan approves Lunsumio + Polivy for relapsed/refractory large B‑cell lymphoma after Phase III SUNMO: ORR 69.7%, PFS 11.5 vs 3.8 months (59% lower progression/death risk); manageable safety.
23 March 2026
GSK’s risvutatug rezetecan granted orphan drug designation for SCLC in Japan
Risvutatug rezetecan, a B7-H3–targeted ADC, showed durable responses in extensive‑stage SCLC in phase I ARTEMIS‑001; global phase III in relapsed ES‑SCLC is underway.
20 March 2026
Petrobras resumes investments in Minas Gerais during Lula visit
During Lula’s visit to Regap (Betim), resumption of investments announced: R$3.8bn (2026–30), up to R$9bn/10 yrs; 8k–36k jobs; +25k bpd capacity (2027) and 13.3 MW solar plant.
19 March 2026
FDA approves Novo Nordisk’s Wegovy HD (7.2 mg) after ~21% weight loss in STEP UP trial
Higher‑dose semaglutide injection approved for adults with obesity after tolerating 2.4 mg; 31% reached ≥25% weight loss. Common AEs: GI symptoms and dysesthesia/altered skin sensation. Available April.
19 March 2026
Novo Nordisk: FDA approves Wegovy HD (semaglutide 7.2 mg) — 20.7% mean weight loss
STEP UP: ~31% achieved ≥25% loss; STEP UP T2D mean loss 14.1%. FDA awarded National Priority Voucher. US launch expected April 2026. Safety/tolerability comparable to prior semaglutide doses.
19 March 2026
GSK: Lynavoy (linerixibat) FDA-approved for cholestatic pruritus in PBC
FDA approved linerixibat for cholestatic pruritus in adults with PBC after GLISTEN phase III showed rapid, sustained itch and sleep improvements. Common AEs: diarrhea, abdominal pain.
19 March 2026
Clariant opens pharma-grade PEG manufacturing plant in Texas
GMP-compliant excipient production strengthens supply-chain resilience, shortens lead times, and improves continuity and traceability for pharma customers across North & Latin America.
19 March 2026
Equinor Annual Report 2025
Record production and strong cash results in 2025; safety improved; adjusted operating income $27.6B; production 2,137 mboe/d; renewables +25%; emissions −34% since 2015.
18 March 2026
Petrobras Contracts 8 Thermoelectric Plants in 2026 Capacity Reserve Auction
Result secures ~R$4bn annual fixed revenue, requires signing CRCAPs, proving firm fuel supply and meeting ONS operational rules; portfolio totals 4.9 GW, supporting SIN availability
18 March 2026
Eni 2025 Financial Statements
Board approved 2025 Annual Report: consolidated net profit €2,608m, parent €4,429m. 4th dividend scheduled (ex-div May 18, pay May 20). AGM May 6; governance, sustainability and remuneration reports to be published.
18 March 2026
Johnson & Johnson FDA approves ICOTYDE (icotrokinra) for first‑line systemic treatment of plaque psoriasis
First targeted oral IL‑23 receptor peptide approved for moderate‑to‑severe plaque psoriasis in adults and ≥12 (≥40kg). Once‑daily pill; ~70% IGA0/1, 55% PASI90 at Week16; safety like placebo.
← Previous
Next →
